title: Plasma interferon-gamma-inducible protein-10 can predict virologic response to hepatitis C virus therapy in HIV/HCV-coinfected patients with HCV genotype 1.
authors.forename: Ana
authors.initials: A
authors.lastname: Vargas
authors.forename: Juan
authors.initials: J
authors.lastname: Berenguer
authors.forename: Pablo
authors.initials: P
authors.lastname: Ryan
authors.forename: Pilar
authors.initials: P
authors.lastname: Catalán
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: López
authors.forename: Jaime
authors.initials: J
authors.lastname: Cosín
authors.forename: Pilar
authors.initials: P
authors.lastname: Miralles
authors.forename: Salvador
authors.initials: S
authors.lastname: Resino
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D054357:Chemokine CXCL10 / Q000097:blood*; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008297:Male; D011237:Predictive Value of Tests; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D054357:Chemokine CXCL10; D016898:Interferon-alpha; D012254:Ribavirin